Press Releases

Sep 6, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016

Jul 13, 2016 • 7:00 AM EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016

Jun 22, 2016 • 7:05 AM EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology

Jun 20, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016

Jun 8, 2016 • 7:00 AM EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016

Mar 31, 2016 • 7:05 AM EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update

Mar 10, 2016 • 7:35 AM EST Matinas BioPharma to Present at the 28th Annual ROTH Conference

Mar 7, 2016 • 7:05 AM EST Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections

Feb 10, 2016 • 8:05 AM EST Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology

Feb 8, 2016 • 7:05 AM EST Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B